Wu Qian, Lv Qianyu, Liu Xiao'an, Ye Xuejiao, Cao Linlin, Wang Manshi, Li Junjia, Yang Yingtian, Li Lanlan, Wang Shihan
Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China.
Capital University of Medical, Beijing, China.
Front Pharmacol. 2023 Jan 20;14:1083875. doi: 10.3389/fphar.2023.1083875. eCollection 2023.
Atherosclerosis (AS) is a chronic inflammatory disease that is a major cause of cardiovascular diseases (CVDs), including coronary artery disease, hypertension, myocardial infarction, and heart failure. Hence, the mechanisms of AS are still being explored. A growing compendium of evidence supports that the activity of the mechanistic/mammalian target of rapamycin (mTOR) is highly correlated with the risk of AS. The mTOR signaling pathway contributes to AS progression by regulating autophagy, cell senescence, immune response, and lipid metabolism. Various botanical drugs and their functional compounds have been found to exert anti- AS effects by modulating the activity of the mTOR signaling pathway. In this review, we summarize the pathogenesis of AS based on the mTOR signaling pathway from the aspects of immune response, autophagy, cell senescence, and lipid metabolism, and comb the recent advances in natural compounds from botanical drugs to inhibit the mTOR signaling pathway and delay AS development. This review will provide a new perspective on the mechanisms and precision treatments of AS.
动脉粥样硬化(AS)是一种慢性炎症性疾病,是心血管疾病(CVD)的主要原因,包括冠状动脉疾病、高血压、心肌梗死和心力衰竭。因此,AS的发病机制仍在探索中。越来越多的证据支持雷帕霉素机制性/哺乳动物靶标(mTOR)的活性与AS风险高度相关。mTOR信号通路通过调节自噬、细胞衰老、免疫反应和脂质代谢促进AS进展。已发现各种植物药及其功能化合物可通过调节mTOR信号通路的活性发挥抗AS作用。在本综述中,我们从免疫反应、自噬、细胞衰老和脂质代谢等方面总结基于mTOR信号通路的AS发病机制,并梳理植物药中天然化合物抑制mTOR信号通路和延缓AS发展的最新进展。本综述将为AS的发病机制和精准治疗提供新的视角。